140 related articles for article (PubMed ID: 25219707)
1. Tumor necrosis factor-alfa inhibitors in pregnancy: to prescribe, or not to prescribe, that is the question.
Murase JE; Butler DC
J Am Acad Dermatol; 2014 Oct; 71(4):831-2. PubMed ID: 25219707
[No Abstract] [Full Text] [Related]
2. The use of tumor necrosis factor inhibitors in pregnancy: what is the evidence?
Kivelevitch DN; Ryan C; Menter A
J Am Acad Dermatol; 2014 Oct; 71(4):829-31. PubMed ID: 25219705
[No Abstract] [Full Text] [Related]
3. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation.
Butler DC; Heller MM; Murase JE
J Am Acad Dermatol; 2014 Mar; 70(3):417.e1-10; quiz 427. PubMed ID: 24528912
[TBL] [Abstract][Full Text] [Related]
4. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.
Murase JE; Heller MM; Butler DC
J Am Acad Dermatol; 2014 Mar; 70(3):401.e1-14; quiz 415. PubMed ID: 24528911
[TBL] [Abstract][Full Text] [Related]
5. An approach to preventing adverse drug effects during pregnancy.
Prescrire Editorial Staff
Prescrire Int; 2014 Jan; 23(145):24-6. PubMed ID: 24516911
[No Abstract] [Full Text] [Related]
6. Prescribing for the pregnant patient.
Mehta N; Chen K; Powrie RO
Cleve Clin J Med; 2014 Jun; 81(6):367-72. PubMed ID: 24891538
[TBL] [Abstract][Full Text] [Related]
7. Oral isotretinoin and pregnancy prevention programmes.
Thiboutot D; Gollnick H; Bettoli V; Dréno B; Kang S; Leyden JJ; Shalita A; Torres V;
Br J Dermatol; 2012 Feb; 166(2):466-7; author reply 467-8. PubMed ID: 21985025
[No Abstract] [Full Text] [Related]
8. Research challenges for drug-induced birth defects.
Mitchell AA
Clin Pharmacol Ther; 2016 Jul; 100(1):26-8. PubMed ID: 27037730
[TBL] [Abstract][Full Text] [Related]
9. Isotretinoin and iPledge: a view of results.
Maloney ME; Stone SP
J Am Acad Dermatol; 2011 Aug; 65(2):418-419. PubMed ID: 21763564
[No Abstract] [Full Text] [Related]
10. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
11. Isotretinoin and pregnancy prevention: do we need to take a long, hard look at ourselves?
Altman EM
JAMA Dermatol; 2014 Apr; 150(4):361-2. PubMed ID: 24258339
[No Abstract] [Full Text] [Related]
12. Dermatologic drugs, pregnancy, and lactation. A conservative guide.
Reed BR
Arch Dermatol; 1997 Jul; 133(7):894-8. PubMed ID: 9236528
[TBL] [Abstract][Full Text] [Related]
13. Medications in pregnancy and lactation.
Clementi M; Cassina M; Di Gianantonio E
Obstet Gynecol; 2009 Jul; 114(1):166. PubMed ID: 19546776
[No Abstract] [Full Text] [Related]
14. [Dermatological treatment and pregnancy].
Piérard-Franchimont C; Gérardy-Goffin F; Piérard GE
Rev Med Liege; 1993 Sep; 48(9):505-11. PubMed ID: 8210844
[No Abstract] [Full Text] [Related]
15. [Off-label use].
Fritz K; Augustin M; John SM
Hautarzt; 2013 Oct; 64(10):727. PubMed ID: 24150819
[No Abstract] [Full Text] [Related]
16. Patient-physician-regulator triad.
Valois M; Peterson R; Bouthillier L
CMAJ; 2005 Jan; 172(1):15; author reply 18. PubMed ID: 15632390
[No Abstract] [Full Text] [Related]
17. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity.
De Santis M; Straface G; Cavaliere A; Nobili E; Caruso A
Prev Med; 2007; 45(2-3):243-4. PubMed ID: 17640721
[No Abstract] [Full Text] [Related]
18. Accutane registry compulsory in US, but not Canada.
Andresen M
CMAJ; 2006 Jun; 174(12):1701. PubMed ID: 16754892
[No Abstract] [Full Text] [Related]
19. Are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin.
Fain K; Alexander GC
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1258-62. PubMed ID: 24115318
[No Abstract] [Full Text] [Related]
20. Comments on: are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin.
Van Bennekom CM; Mitchell AA
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):439. PubMed ID: 24706419
[No Abstract] [Full Text] [Related]
[Next] [New Search]
